ScholarRock's newly approved drug for the rare disease spinal muscular atrophy blocks myostatin to prevent muscle loss. This same mechanism is now being redeployed as a major strategy to counteract the muscle loss side effect of GLP-1 obesity drugs, potentially opening a massive new market.
Even with court injunctions blocking specific anti-immigration rules, the unpredictable and hostile environment created by the administration has become a policy in itself. This "uncertainty policy" has eroded trust and is a more powerful deterrent for international scientists than any individual regulation.
The significant clinical time commitment for psychedelic therapies like LSD, which can require 8-10 hours of monitoring, is a major commercialization hurdle. This will likely bifurcate the market, creating high demand for faster-acting compounds like 5-MEO-DMT that reduce the logistical and cost burden on clinics and patients.
The change to "Novo" and marketing language prioritizing "consumer" over "patient" reveals a two-step strategy. After successfully establishing obesity as a serious disease to secure insurance reimbursement, Novo is now shifting to marketing its drugs directly to consumers as lifestyle brands.
Recent acquisitions, such as Eli Lilly buying Atai and AbbVie buying Gigamesh, are the clearest signal that psychedelic therapies are no longer a niche R&D area. Major pharmaceutical companies now view the space as a core part of their growth strategy and a substantial business opportunity.